Related Experiment Videos
Therapeutic differentiation in a human rhabdomyosarcoma cell line selected for resistance to actinomycin D
J Prados1, C Melguizo, J A Marchal
1Department of Health Sciences, University of Almería, Spain.
Abstract:
Classical cytotoxic treatment of rhabdomyosarcoma (RMS) is accompanied often by significant morbidity and poor response. The use of cytotoxic agents may induce a multidrug resistance phenotype, which plays an important role in the sensitivity of tumoral cells to drugs. Using actinomycin D, a drug of choice in the treatment of RMS, we induced resistance in the TE.32.7 human RMS cell line. The TE.32.7-DAC-resistant cell line exhibited cross-resistance to vincristine and doxorubicin and showed mdr1/P-glycoprotein over-expression, suggesting that this mechanism was involved in the reduction in intracellular drug concentration and may be responsible for the failure of treatment of RMS with classical cycles of cytotoxics. Furthermore, this resistant cell line showed increased expression of the muscle differentiation markers desmin and alpha-actinin and ultrastructural changes which clearly indicated myogenic differentiation. Our findings suggest that, although this tumor is probably arrested along the normal myogenic pathway to maturation, induction of cell differentiation with anti-neoplastic drugs may be an alternative therapeutic approach. However, the failure of TE.32.7-DAC cells to completely re-enter the program of myogenic differentiation supports the hypothesis that multidrug resistance is a major obstacle in differentiation therapy for RMS.
Insights
Multidrug resistance in rhabdomyosarcoma (RMS) limits treatment efficacy. Inducing differentiation with anti-cancer drugs offers a potential therapeutic avenue, but multidrug resistance remains a significant challenge.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Classical cytotoxic chemotherapy for rhabdomyosarcoma (RMS) often results in significant morbidity and limited treatment response.
- Multidrug resistance (MDR) is a key mechanism contributing to the ineffectiveness of conventional cytotoxic agents in RMS treatment.
- P-glycoprotein (mdr1) overexpression is a common cause of MDR, reducing intracellular drug accumulation.
Purpose of the Study:
- To investigate the role of multidrug resistance in rhabdomyosarcoma (RMS) treatment.
- To explore the potential of inducing myogenic differentiation as an alternative therapeutic strategy for RMS.
- To assess the impact of multidrug resistance on differentiation therapy in RMS.
Main Methods:
- Induction of actinomycin D resistance in the TE.32.7 human RMS cell line to create a multidrug-resistant (MDR) cell line (TE.32.7-DAC).
- Evaluation of cross-resistance patterns to vincristine and doxorubicin in the resistant cell line.
- Assessment of mdr1/P-glycoprotein expression levels and myogenic differentiation markers (desmin, alpha-actinin) using Western blotting and ultrastructural analysis.
Main Results:
- The TE.32.7-DAC resistant cell line exhibited cross-resistance to vincristine and doxorubicin, associated with mdr1/P-glycoprotein overexpression.
- The resistant cell line displayed increased expression of myogenic differentiation markers (desmin, alpha-actinin) and ultrastructural evidence of myogenic differentiation.
- Complete re-entry into the myogenic differentiation program was hindered in the resistant cells, suggesting a barrier to differentiation therapy.
Conclusions:
- Multidrug resistance, mediated by P-glycoprotein, significantly reduces intracellular drug concentrations and contributes to treatment failure in RMS.
- Inducing myogenic differentiation with anti-neoplastic drugs presents a potential alternative therapeutic approach for RMS.
- Multidrug resistance poses a major obstacle to successful differentiation therapy in RMS, necessitating strategies to overcome MDR.